1. Introduction
The porphyrias are metabolism diseases caused by the deficiency of a specific enzyme in the heme biosynthetic pathway. Porphyrias have been classified into bone marrow and liver types on the basis of the predominant site of porphyrin production site. Recent classification of porphyrias shows acute porphyria and cutaneous porphyria according to the condition of signs (Table 1). Eryhtropoietic protoporphyria (EPP; OMIM 177000) is an autosomal dominant disease of porphyrin metabolism caused by decreased activity of the ferrochelatase (FECH; E.C. 4.99.1.1) that is the terminal enzyme in the heme biosynthetic pathway (Fig. 1). This type of porphyria was first described in 1953 by Kosenow and Treibs and this description was completed in 1961 by Magnus et al.1 Decrease in FECH activity causes excess protoporphyrin induction, leading to photosensitivity of the skin and liver dysfunction. Photosensitivity starting from childhood makes quality of life low and liver dysfunction may lead to hepatic failure and death. In this session, we describe (1) clinical features of EPP, (2) genetic characteristics of EPP, and (3) mice models of EPP.
2. The clinical features of EPP
2.1. Skin
Suspicion of EPP should be raised by the history of screaming or skin pain in a child on going outdoors.2 However, it is very difficult to suspect EPP if clinical manifestation are minimum. The characteristics of photosensitivity in EPP are first a burning, stinging sensation appearing immediately at sun exposure followed by erythema, edema and purpura.1 We reported a 1-year-old male infant with EPP who showed only erythema after sun exposure (Fig. 2).3 Infant patients are unable to complain the abnormal sensations and pain. Cutaneous signs are characterized with erythema, swelling, papules, vesicles, small blood blisters, crusts, and scars. Scar, the most distinct skin lesion, is small, polygonal or linear, depressed or slightly elevated (Figs. 3 and 4). With the progression of the disease and if sun exposure is not avoided, chronic lesions develop progressively with skin thickening (waxy lichenification on the dorsa of the hands) and scarring (pseudorhagades formation in the lips).1
Minder performed a systematic review of treatment options for dermal photosensitivity in EPP.4 Sixteen of 25 relevant studies dealed with β-carotene. However, the results from β-carotene were strongly contradictory and efficacy was inversely correlated with study quality.4 Afamelanotide, an a-melanocyte-stimulating hormone analogue, was reported to be effective for EPP.5 Afamelanotide, making melanin density of the skin increase, was effective for photosensitivity from artificial light and sunlight in 5 EPP patients.5 Moreover, Petersen reported that oral treatment with a high daily dosage of zinc sulphate during the spring and summer reduced light sensitivity and pain in 71% of 14 EPP patients.6 They speculated that zinc treatment in EPP patients may have provided antioxidant protection of cellular membranes against the deleterious photodynamic effects of protoporphyrin IX (PPIX) accumulation.6 Photoprotection against visible light that absorbs PPIX is still a mainstream in the care of EPP patients, although these novel approaches were reported. However, some reports raised awareness about vitamin D deficiency due to sun avoidance in EPP. Spelt reported that 46% of 48 Dutch EPP patients showed decreased level of serum 25-hydroxyvitamin D.7 Vitamin D deficiency was high in male patients and correlated with the severity of EPP.7 Holme also reported that 17% was deficient and 63% was insufficient in serum 25-hydroxyvitamin D levels of 201 United Kingdom (UK) patients with EPP.8 Then, we should care for vitamin D deficiency in EPP patients performing strict photoprotection.
2.2. Liver
Mild abnormalities of liver function may be detected in about 10% of patients of EPP and liver failure affects about 5-20%.2, 9 Excess PP with any origin is excreted by the liver into bile and enters an enterohepatic circulation.10 Excess PP becomes insoluble in bile and exerts cholestatic effects, structural changes from mild inflammation to fibrosis and cirrhosis.10 Liver diseases include cholelithiasis, gallstones, biochemical abnormalities (aspartate amino transferase (AST), alanine amino transferase (ALT), gamma-glutamyl transpeptidase (gamma-GTP), alkaline phosphatase (ALP)), cirrhosis, and terminal liver failure. PP deposition in hepatocytes is invariable, whereas histological evidence of damage is less common; electron microscopy shows ultrastructural damage in most patients with EPP.10
Liver transplantation for liver failure in EPP patients started in 1980. Dowman investigated 5 UK cases receiving liver transplant for EPP-related liver diseases.11 Two patients died at 44 and 95 months from causes unrelated to liver disease, while 3 patients were alive at 22.4 years, 61 months and 55 months after liver plant.11 In spite of a good long-term survival, a high rate of postoperative biliary stricturing requiring multiple biliary interventions was seen.11 Wahlin also investigated that 35 liver transplants for protoporphyric liver disease in 31 European patients between 1983 and 2008.12 The overall rate of disease recurrence in the graft was high (69%), although they showed good survival rates, 77% at 1 year and 66% at 5 and 10 years.12
As liver transplant does not correct the constitutional deficiency of FECH, there is a risk of recurrence of liver disease even after liver transplant due to continuing overproduction of protoporphyrin.9 Then, bone marrow transplantation may be considered in liver allograft recipients in the future.
2.3. Biochemistry and blood test
Increase of PP in the blood and stool is the most specific in EPP. However, urinary porphyris (uroporphyrin, coproporphyrin, porphobirinoge, δ-aminolevulic acid) remain as normal levels. Many patients with EPP have an apparent mild anemia with a microcytic hypochromic blood film.2 However, administration of iron is not recommended since iron sometimes exacerbate the porphyria.
3. Genetic characteristics of EPP
EPP is a disease caused by decreased activity of the ferrochelatase (FECH; E.C. 4.99.1.1) that is the final enzyme in the heme biosynthetic pathway. The
Gouya reported that (1) coinheritance of a
Genetic variants in the
Nakano firstly identified two novel mutations in two Japanese families using direct sequence analysis of the entire coding region of the FECH gene.17 The proband in the first family was heterozygous for a 3-bp deletion from nucleotide positions 853 to 855 in exon 8, designated delCAA853.17 Pedigree analysis of the other family members showed that the mother and two sisters, all asymptomatic, were heterozygous for this mutation.17 Restriction fragment polymorphism analysis indicated that the proband was homozygous for the IVS3-48C polymorphism, while other family members, asymptomatic carriers, had a wild-type T at position IVS3-48 in
In UK, Whatley identified large deletions of the
In Canada, Pierro identified a 10,376 bp deletion (c.1-7887_67+2422del) including a portion of the upstream intergenic region, the promoter, the exon 1 and a portion of intron 1 in a Canadian EPP patient of Italian origin.20 Li also reported that a Canadian EPP patient had a novel large deletion [c.1-9628_67+2871del12566 bp] and three polymorphisms [c.1-251A>G, c.68-23C>T and c.315-48T>C] in trans to the deletion in
In China, Zhou identified a novel IVS1+1G→C mutation of the FECH gene in a Chinese EPP family.22 Fong identified a recurrent splice site mutation, c.67+1G>C, and a novel nonsense mutation, p.Y191X, in 2 unrelated Chinese families.23 Their investigation revealed that the allele frequency of IVS3-48C in Hong Kong population (28%) was lower than that of Japanese population but higher than that of European populations.23 Ma identified a novel splicing
In Argentina, Parera detected three novel and two previously described mutations in five Argentinean EPP families; (1) a deletion (451delT) producing a stop codon located 18 codons downstream from the mutation, (2) IVS1-2A>G leading to exon 2 skipping, (3) IVS4-2A>G, which causes the loss of the first 48 bp of exon 5, (4) C343T, and (5) 400delA.25 Colombo’s study of 19 Argentina EPP patients identified three novel (p.S222N; p.R298X and p.R367X) and seven already known (g.12490_18067del; p.R115X; p.I186T; c.580_584delTACAG; c.598+1G>T; p.Y209X and p.W310X) and indicated the possibility of c.315-48C variant in
In Spain, Herrero reported that three novel mutations (IVS4+1delG, 347-351delC, and 130_147dupl 18) and IVS3-48C low-expression allele in ten of 11 EPP patients.26 They also estimated the frequency of the IVS3-48C allele among 180 nonporphyric Spanish individuals as 5.2%.26 In South Africa, Parker identified ten sequence variations; IVS3-48T ⁄ C polymorphism, five further polymorphisms, a 5-bp deletion in exon 7 (757_761delAGAAG), two previously described splice-site mutations (IVS3+2T>G and IVS7+1G>A), and a novel 7-bp deletion in exon 4 (356_362delTTCAAGA).27 In Portugal, Morais identified heterozygosity for a novel mutation (c.1052delA) in
Recently, an association of EPP and palmar keratoderma has been reported. Méndez detected a homozygous inheritance of a novel missense mutation Q285R, a homozygous A-to-G transition, c.854A>G, in the
4. Mice models of EPP
Mice models of EPP are useful to investigate the effects of FECH on iron metabolism in EPP. Lyoumi investigated hematologic and iron status in FECH-deficient Fechm1Pas mutant mice.31 Their mice had microcytic hypochromic anemia without ringed sideroblasts, little or no hemolysis, and no erythroid hyperplasia, whereas the mice showed no tissue iron deficiency but did a redistribution of iron stores from peripheral tissues to the spleen, with a 2- to 3-fold increase in transferrin expression of mRNA and protein levels.31 Using Fechm1Pas mutant mice with the BALB/c and C57BL/6 backgrounds, Lyoumi demonstrated that BALB/c backgrounded Fechm1Pas mice had more severe cholestasis, fibrosis with portoportal bridging, bile acid regurgitation, sclerosing cholangitis, and hepatolithiasis as compared with the mice with C57BL/6 background.32
5. Conclusion
EPP is an autosomal dominant disease of porphyrin metabolism that is characterized with photosensitivity and liver disease. We have reviewed recent advances of clinical features of EPP, genetic characteristics of EPP, and mice models of EPP. Further studies of genetic analysis and FECH-deficient mice will provide us the new strategy for the treatment of EPP.
References
- 1.
Eryhtropoietic protoporphyria. Photodermatol Photomed PhotoimmunolLecha M 2003 19 142 6 - 2.
Diagnosis and management of the erythropoietic protoporphyris. Dermatol TherMurphy G. M 2003 16 57 64 - 3.
An infantile case of erythropoietic protoporphyria with a decreased mRNA level of ferrocheratase. HifuKawada A Gomi H Shiraishi H Hatanaka K Matsuo I Inafuku K Takamori K Tezuka T 2001 43 111 5 - 4.
A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol BiolMinder E. I Schneider-yin X Steurer J Bachmann L. M 2009 55 84 97 - 5.
An α-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Eng J MedHarms J Lautenschlager S Minder C. E Minder E. I 2009 360 306 7 - 6.
Zinc sulphate: a new concept of treatment of erythropoietic protoporphyria. Br J DermatolPetersen A. B Philipsen P. A Wulf H. C 2012 166 1129 31 - 7.
Spelt JMC Rooij FWM, Wilson JHP, Zandbergen AAM. Vitamin D deficiency in patients with erythropoietic protoporphyria. J Inherit Metab Dis2009 doi: s10545-008-1037-0. - 8.
Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. Br J DermatolHolme S. A Anstey A. V Badminton M. N Elder G. H 2008 159 211 3 - 9.
Liver disease and erythropoietic protoporphyria: a concise review. World J Gastroenterol.Casanova-gonzález M. J Trapero-marugán M Jones E. A Moreno-otero R 2010 16 4526 31 - 10.
Liver disease in erythropoietic protoporphyria: insights and implications for management. GutAnstey A. V Hift R. J 2007 56 1009 18 - 11.
UK experience of liver transplantation for erythropoietic protoporphyria. J Inherit Metab DisDowman J. K Gunson B. K Mirza D. F Badminton M. N Newsome P. N 2011 34 539 45 - 12.
P. Liver transplantation for erythropoietic protoporphyria in Europe. Liver TransplWahlin S Stal P Adam R Karam V Porte R Seehofer D Gunson B. K Hillingsø J Klempnauer J. L Schmidt J Alexander G O Grady J Clavien P. A Salizzoni M Paul A Rolles K Ericzon B. G Harper 2011 17 1021 6 - 13.
Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. BloodGouya L Puy H Lamoril J Silva V. D Grandchamp B Nordmann Y Deybach J-C 1999 93 2105 10 - 14.
A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria. Cell Mol BiolMinder E. I Gouya L Schneider-yin X Deybach J. C 2002 48 91 6 - 15.
Enríquez de Salamanca R, Batlle AMC, Parera VE. Functional associations of genetic variants involved in the clinical manifestation of erythropoietic protoporphyria in the argentinean population. J Eur Acad Dermatol VenereolColombo F. P Rossetti M. V Méndez M Martínez J. E j.2012 doi:1468 3083 x. - 16.
Balwani M Desnick R. J The porphyrias: advances in diagnosis and treatment Blood2012 doi:10.1182/ - 17.
Novel Ferrochelatase Mutations in Japanese Patients with erythropoietic protoporphyria: high frequency of the splice site modulator IVS3-48C polymorphism in the Japanese population. J Invest DermatolNakano H Nakano A Toyomaki Y Ohashi S Harada K Moritsugu R Takeda H Kawada A Mitsuhashi Y Hanada K 2006 126 2717 9 - 18.
Gene dosage analysis identifies large deletions of the gene in 10% of families with erythropoietic protoporphyria. J Invest DermatolWhatley S. D Mason N. G Holme S. A Anstey A. V Elder G. H Badminton M. N 2007 127 2790 4 - 19.
Late presentation of erythropoietic protoporphyria: case report and genetic analysis of family members. Br J DermatolBerroeta L Man I Goudie D. R Whatley S. D Elder G. H Ibbotson S. H 2007 157 1030 1 - 20.
Di Pierro E Brancaleoni V, Besana V, Ausenda S, Drury S, Cappellini MD. A 10376 bp deletion of FECH gene responsible for erythropoietic protoporphyria. Blood Cells Mol Dis2008 40 233 6 - 21.
Di Pierro E, Brancaleoni V, Cappellini MD, Steensma DP. A novel large deletion and three polymorphism in the FECH gene associated with erythropoietic protoporphyria. Clin Chem lab MedLi C 2009 47 44 6 - 22.
A novel mutation of the FECH gene in a Chinese family with erythropoietic protoporphyria. J Dermatol SciZhou S. N Xiao S. X Peng Z. H Li B. X Li X. L Li Y Luo S. J 2007 48 145 7 - 23.
DNA-based diagnosis of erythropoietic protoporphyria in two families and the frequency of a low-expression allele in a Chinese population. Clin Chim ActaLau K. C Lam C. W 2009 400 132 4 - 24.
A novel splicing mutation and haplotype analysis of the gene in a Chinese family with erythropietic protoporphyria. J Eur Acad Dermatol VenereolMa J Xiao S An J Wang X Xu Q Dong Y Feng Y Wang J 2010 24 726 9 - 25.
De Rooij FWM. Novel null-allele mutations and genotype-phenotype correlation in Argentinean patients with erythropoietic protoporphyria. Mol MedParera V. E Koole R. H Minderman G Edixhoven A Rossetti M. V Batlle A 2009 15 425 31 - 26.
Clinical, biochemical, and genetic study of 11 patients with erythropoietic protoporphyria including one with homozygous disease. Arch DermatolHerrero C To-figueras J Badenas C Méndez M Serrano P Enríquez-salamanca R Lecha M 2007 143 1125 9 - 27.
Molecular characterization of erythropoietic protoporphyria in South Africa. Br J DermatolParker M Corrigall A. V Hift R. J Meissner P. N 2008 159 182 91 - 28.
Erythropoietic protoporphyria: a family study and report of a novel mutation in the FECH gene. Eur J DermatolMorais P Mota A Baudrier T Trigo F Oliveira J. P Cerqueira R Palmeiro A Tavares P Azevedo F 2011 21 479 83 - 29.
A homozygous mutation in the ferrochelatase gene underlies erythropoietic protoporphyria associated with palmar keratoderma. Br J DermatolMéndez M Poblete-gutiérrez P Morán-jiménez M. J Rodriguez M. E Garrido-astray M. C Fontanellas A Frank J De Salamanca R. E 2009 160 1330 4 - 30.
A homoallelic FECH mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma. J Eur Acad Dermatol VenereolMinder E. I Schneider-yin X Mamet R Horev L Neuenschwander S Baumer A Austerlitz F Puy H Schoenfeld N 2010 24 1349 53 - 31.
Lyoumi S Abitbol M Andrieu V Henin D Robert E Schmitt C Gouya L De Verneuil H Deybach J. C Montagutelli X Beaumont C Puy H Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. 2007 109 811 8 - 32.
Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. GastroenterologyLyoumi S Abitbol M Rainteau D Karim Z Bernex F Oustric V Millot S Letteron P Heming N Guillmot L Montagutelli X Berdeaux G Gouya L Poupon R Deybach J. C Beaumont C Puy H 2011 141 1509 19